Skip to content
Oncorena AB logo

Oncorena AB Alternatives & Competitors

12 companies similar to Oncorena AB — Developing a first-in-class treatment for advanced renal cancer

Companies similar to Oncorena AB

Cybrexa Therapeutics logo — alternative to Oncorena AB

Cybrexa Therapeutics

Changing the paradigm for cancer treatment through the development of antigen-independent...

Cavion logo — alternative to Oncorena AB

Cavion

Empowering therapies for cancer and neurologic diseases through pioneering ion channel inh...

Jounce Therapeutics, Inc. logo — alternative to Oncorena AB

Jounce Therapeutics, Inc.

Daring to create a world immune to cancer.

Cinclus Pharma logo — alternative to Oncorena AB

Cinclus Pharma

Developing effective treatment for gastric acid related diseases.

Rival Readout

Competing with Oncorena AB? We do this properly.

10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.

Book a 7-day Readout
Pacylex Pharmaceuticals, Inc. logo — alternative to Oncorena AB

Pacylex Pharmaceuticals, Inc.

A new target in cancer care - triggering selective lethality with a new class of drugs.

Abcuro, Inc logo — alternative to Oncorena AB

Abcuro, Inc

Developing immunotherapies for autoimmune diseases and cancer

Creative BioTherapeutics LLC logo — alternative to Oncorena AB

Creative BioTherapeutics LLC

An emerging biotech discovering & developing novel therapies for cancer and viruses where...

Tango Therapeutics logo — alternative to Oncorena AB

Tango Therapeutics

Targeting tumor suppressor loss to unmask vulnerabilities for the next generation of preci...

iOnctura logo — alternative to Oncorena AB

iOnctura

Developing precision small molecules to combat hard-to-treat tumors.

ImmunoMet Therapeutics, Inc. logo — alternative to Oncorena AB

ImmunoMet Therapeutics, Inc.

Targeting Metabolic Reprogramming in Fibrosis and Oncology

Acrivon Therapeutics, Inc. logo — alternative to Oncorena AB
Sierra Oncology logo — alternative to Oncorena AB

Sierra Oncology

We are on a mission to deliver transformative therapies that treat rare forms of cancer.

About Oncorena AB

Oncorena AB is a biotechnology startup headquartered in Lund, Sweden, founded in 2011. The company is focused on developing a first-in-class treatment for advanced renal cancer, utilizing a natural substance as the basis for their breakthrough therapy. Oncorena has completed all preclinical studies and is now entering...

Business keywords

Oncorena, Renal Cancer Treatment, Advanced Kidney Cancer, Drug Development, Oncology, Clinical Trials, Preclinical Studies, Cancer Therapy, Swedish Biotech, Lund, Orellanine, Anti-tumor Activity, Early-stage Clinical Development, Drug Candidate

Frequently Asked Questions

Companies similar to Oncorena AB include Cybrexa Therapeutics, Cavion, Jounce Therapeutics, Inc., Cinclus Pharma, Pacylex Pharmaceuticals, Inc.. They work in Biotechnology and Health Care and share Oncorena AB's focus on drug development, oncology and clinical trials.
Bounce Watch lists 12 companies that share Oncorena AB's industries and are closest to it in business tags, services, target customers, business model and size.
Oncorena AB is a biotechnology startup headquartered in Lund, Sweden, founded in 2011. The company is focused on developing a first-in-class treatment for advanced renal cancer, utilizing a natural substance as the basis for their breakthrough therapy. Oncorena has completed all preclinical studies and is now entering...

From the desk

Mapping a market? Start with a Rival Readout.

In 7 business days we read 10 rivals around Oncorena AB: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.

Compiled from the BounceWatch company index. We last looked at Oncorena AB on 11 Sep 2024. The 12 companies listed here were last checked between 11 Sep 2024 and 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout